<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2780">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070704</url>
  </required_header>
  <id_info>
    <org_study_id>NN9068-4331</org_study_id>
    <secondary_id>U1111-1185-0871</secondary_id>
    <nct_id>NCT03070704</nct_id>
  </id_info>
  <brief_title>Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India</brief_title>
  <official_title>A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this study is to evaluate long term safety and
      efficacy in patients with type 2 diabetes mellitus in routine clinical practice in India.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2017</start_date>
  <completion_date type="Anticipated">April 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of incidence of treatment emergent Adverse Events (AEs)</measure>
    <time_frame>Year 0-1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAEs)</measure>
    <time_frame>Year 0-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Drug Reactions (SADRs)</measure>
    <time_frame>Year 0-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Year 0-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of confirmed severe hypoglycaemic events</measure>
    <time_frame>Year 0-1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the level of glycosylated haemoglobin (HbA1c)</measure>
    <time_frame>Year 0, Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the level of Fasting Plasma/Blood Glucose (FPG/FBG) from baseline</measure>
    <time_frame>Year 0, Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the target level of HbA1c below 7%</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Year 0, Year 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients withdrawn due to ineffective therapy</measure>
    <time_frame>Year 1</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin degludec /liraglutide</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin degludec / liraglutide</intervention_name>
    <description>Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician</description>
    <arm_group_label>Insulin degludec /liraglutide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Based on the clinical judgement of their treating physician, patients with type 2 diabetes
        mellitus will be initiated on Xultophy™ according to routine clinical practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any study-related activities. Study-related
             activities are any procedures that are related to the recording of data and
             determining the suitability for the study according to the protocol. Some specific
             historical data collected before informed consent is obtained can be used as baseline
             data (HbA1c, FPG/FBG and others)

          -  The decision to initiate treatment with commercially available Xultophy™ has been
             made by the patient/Legally Acceptable Representative (LAR) and the treating
             physician before and independently from the decision to include the patient in this
             study

          -  Male or female, age at least 18 years at the time of signing the informed consent

          -  Patients diagnosed with type 2 diabetes mellitus

          -  Patients who are scheduled to start treatment with Xultophy™ based on the clinical
             judgement of their treating physician

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to Xultophy™, any of the active substances, any
             of the excipients or any related products

          -  Previous participation in this study. Participation is defined as signed informed
             consent

          -  Mental incapacity, unwillingness or language barriers hindering adequate
             understanding or cooperation

          -  Females who are pregnant, breast-feeding or intend to become pregnant within the
             following 12 months

          -  Patients who are participating in other studies or clinical trials.

          -  Any disorder which in the opinion of the Physician might jeopardise subject's safety
             or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical regisstry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>February 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
